首页> 外文期刊>Journal of drug targeting >Improvement of tetracaine antinociceptive effect by inclusion in cyclodextrins
【24h】

Improvement of tetracaine antinociceptive effect by inclusion in cyclodextrins

机译:通过包含在环糊精中改善丁卡因的镇痛作用

获取原文
获取原文并翻译 | 示例
           

摘要

Local anesthetics (LA) are among the most important pharmacological compounds used to attenuate or eliminate pain. However, systemic toxicity is still a limitation for LA application, especially for ester-type drugs, such as tetracaine (TTC) that presents poor chemical stability (due to hydrolysis by plasma esterases). Several approaches have been used to improve LA pharmaceutical properties, including the employment of drug-delivery systems. Here we used beta-cyclodextrin (β-CD) or hydroxypropyl-beta-cyclodextrin (HP-β-CD) to develop two new TTC formulations (TTC:β-CD and TTC:HP-β-CD). The inclusion complexes formation, in a 1:1 stoichiometry, was confirmed by differential scanning calorimetry, X-ray diffraction, UV-VIS absorption and fluorescence. Nuclear magnetic resonance (DOSY experiments) revealed that TTC association with HP-β-CD is stronger (Ka=1200mol/L -1) than with β-CD (Ka=845mol/L -1). Moreover, nuclear Overhauser effect (NOE) experiments provided information on the topology of the complexes, where TTC aromatic ring is buried inside the CD hydrophobic cavity. In vitro tests with 3T3 fibroblast cells culture revealed that complexation decreased TTC cytotoxicity. In addition, the total analgesic effect of TTC, tested in rats through the infraorbital nerve test, was improved in 36% with TTC:β-CD and TTC:HP-β-CD. In conclusion, these formulations presented potential for future clinical use, by reducing the toxicity and increasing the antinociceptive effect of tetracaine.
机译:局部麻醉药(LA)是用于减轻或消除疼痛的最重要的药理化合物之一。但是,全身毒性仍然是LA应用的局限性,特别是对于酯类药物,例如丁卡因(TTC),其化学稳定性较差(由于血浆酯酶的水解作用)。已经采用了几种方法来改善LA的药物特性,包括采用药物递送系统。在这里,我们使用β-环糊精(β-CD)或羟丙基-β-环糊精(HP-β-CD)开发了两种新的TTC制剂(TTC:β-CD和TTC:HP-β-CD)。通过差示扫描量热法,X射线衍射,UV-VIS吸收和荧光证实了以1:1化学计量的包合物形成。核磁共振(DOSY实验)表明,TTC与HP-β-CD的缔合(Ka = 1200mol / L -1)比与β-CD(Ka = 845mol / L -1)强。此外,核Overhauser效应(NOE)实验提供了有关配合物拓扑结构的信息,其中TTC芳香环埋在CD疏水腔内。用3T3成纤维细胞培养物进行的体外测试显示,复合物可降低TTC的细胞毒性。此外,TTC:β-CD和TTC:HP-β-CD通过眶下神经试验对大鼠进行的TTC总镇痛作用提高了36%。总之,这些制剂通过降低丁卡因的毒性和增加其镇痛作用,为将来的临床应用提供了潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号